PMC:7205724 / 18627-19106 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"651","span":{"begin":28,"end":36},"obj":"Species"},{"id":"652","span":{"begin":406,"end":414},"obj":"Species"},{"id":"653","span":{"begin":140,"end":144},"obj":"Chemical"},{"id":"654","span":{"begin":155,"end":161},"obj":"Chemical"},{"id":"655","span":{"begin":242,"end":260},"obj":"Chemical"},{"id":"656","span":{"begin":348,"end":366},"obj":"Chemical"},{"id":"657","span":{"begin":42,"end":50},"obj":"Disease"}],"attributes":[{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"Tax:9606"},{"id":"A652","pred":"tao:has_database_id","subj":"652","obj":"Tax:9606"},{"id":"A654","pred":"tao:has_database_id","subj":"654","obj":"MESH:D010100"},{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"MESH:D008775"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"MESH:D008775"},{"id":"A657","pred":"tao:has_database_id","subj":"657","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T141","span":{"begin":104,"end":114},"obj":"Body_part"},{"id":"T142","span":{"begin":275,"end":289},"obj":"Body_part"},{"id":"T143","span":{"begin":379,"end":393},"obj":"Body_part"}],"attributes":[{"id":"A141","pred":"fma_id","subj":"T141","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A142","pred":"fma_id","subj":"T142","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A143","pred":"fma_id","subj":"T143","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T138","span":{"begin":42,"end":50},"obj":"Disease"}],"attributes":[{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T229","span":{"begin":24,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T230","span":{"begin":199,"end":200},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T162","span":{"begin":155,"end":161},"obj":"Chemical"},{"id":"T163","span":{"begin":226,"end":240},"obj":"Chemical"},{"id":"T164","span":{"begin":242,"end":260},"obj":"Chemical"},{"id":"T165","span":{"begin":348,"end":366},"obj":"Chemical"}],"attributes":[{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A164","pred":"chebi_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T14","span":{"begin":104,"end":134},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T15","span":{"begin":135,"end":150},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T16","span":{"begin":155,"end":172},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T17","span":{"begin":275,"end":289},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T18","span":{"begin":379,"end":393},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A14","pred":"meddra_id","subj":"T14","obj":"http://purl.bioontology.org/ontology/MEDDRA/10025256"},{"id":"A18","pred":"meddra_id","subj":"T18","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"},{"id":"A15","pred":"meddra_id","subj":"T15","obj":"http://purl.bioontology.org/ontology/MEDDRA/10077710"},{"id":"A16","pred":"meddra_id","subj":"T16","obj":"http://purl.bioontology.org/ontology/MEDDRA/10033316"},{"id":"A17","pred":"meddra_id","subj":"T17","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T80","span":{"begin":78,"end":86},"obj":"http://purl.obolibrary.org/obo/OGMS_0000020"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T103","span":{"begin":155,"end":161},"obj":"Chemical"},{"id":"T104","span":{"begin":226,"end":240},"obj":"Chemical"},{"id":"T105","span":{"begin":242,"end":260},"obj":"Chemical"},{"id":"T106","span":{"begin":348,"end":366},"obj":"Chemical"}],"attributes":[{"id":"A105","pred":"chebi_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A104","pred":"chebi_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A106","pred":"chebi_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A103","pred":"chebi_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T184","span":{"begin":42,"end":50},"obj":"Species"}],"attributes":[{"id":"A184","pred":"ncbi_taxonomy_id","subj":"T184","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T150","span":{"begin":0,"end":299},"obj":"Sentence"},{"id":"T151","span":{"begin":300,"end":479},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"651","span":{"begin":28,"end":36},"obj":"Species"},{"id":"657","span":{"begin":42,"end":50},"obj":"Disease"},{"id":"653","span":{"begin":140,"end":144},"obj":"Chemical"},{"id":"654","span":{"begin":155,"end":161},"obj":"Chemical"},{"id":"655","span":{"begin":242,"end":260},"obj":"Chemical"},{"id":"656","span":{"begin":348,"end":366},"obj":"Chemical"},{"id":"652","span":{"begin":406,"end":414},"obj":"Species"}],"attributes":[{"id":"A651","pred":"pubann:denotes","subj":"651","obj":"Tax:9606"},{"id":"A657","pred":"pubann:denotes","subj":"657","obj":"MESH:C000657245"},{"id":"A654","pred":"pubann:denotes","subj":"654","obj":"MESH:D010100"},{"id":"A655","pred":"pubann:denotes","subj":"655","obj":"MESH:D008775"},{"id":"A652","pred":"pubann:denotes","subj":"652","obj":"Tax:9606"},{"id":"A656","pred":"pubann:denotes","subj":"656","obj":"MESH:D008775"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T18993","span":{"begin":0,"end":3},"obj":"DT"},{"id":"T21718","span":{"begin":4,"end":9},"obj":"NN"},{"id":"T64168","span":{"begin":10,"end":11},"obj":"-LRB-"},{"id":"T66430","span":{"begin":11,"end":13},"obj":"CD"},{"id":"T95152","span":{"begin":13,"end":14},"obj":"-RRB-"},{"id":"T31198","span":{"begin":15,"end":23},"obj":"VBD"},{"id":"T55004","span":{"begin":24,"end":27},"obj":"CD"},{"id":"T65830","span":{"begin":28,"end":36},"obj":"NNS"},{"id":"T56952","span":{"begin":37,"end":41},"obj":"IN"},{"id":"T98815","span":{"begin":42,"end":50},"obj":"NN"},{"id":"T69048","span":{"begin":51,"end":54},"obj":"WP"},{"id":"T75376","span":{"begin":55,"end":67},"obj":"VBD"},{"id":"T59786","span":{"begin":68,"end":77},"obj":"VBG"},{"id":"T24326","span":{"begin":78,"end":86},"obj":"NNS"},{"id":"T13700","span":{"begin":86,"end":87},"obj":"-COMMA-"},{"id":"T79561","span":{"begin":88,"end":92},"obj":"FW"},{"id":"T83448","span":{"begin":92,"end":93},"obj":"-COMMA-"},{"id":"T77014","span":{"begin":94,"end":103},"obj":"VBD"},{"id":"T40148","span":{"begin":104,"end":114},"obj":"NN"},{"id":"T31095","span":{"begin":115,"end":120},"obj":"NN"},{"id":"T13833","span":{"begin":121,"end":124},"obj":"CC"},{"id":"T80531","span":{"begin":125,"end":134},"obj":"VBD"},{"id":"T26060","span":{"begin":135,"end":144},"obj":"NN"},{"id":"T3471","span":{"begin":145,"end":150},"obj":"NN"},{"id":"T11859","span":{"begin":151,"end":154},"obj":"CC"},{"id":"T6067","span":{"begin":155,"end":161},"obj":"NN"},{"id":"T65980","span":{"begin":162,"end":172},"obj":"NN"},{"id":"T58632","span":{"begin":172,"end":173},"obj":"-COMMA-"},{"id":"T52543","span":{"begin":174,"end":183},"obj":"VBG"},{"id":"T84435","span":{"begin":184,"end":193},"obj":"NN"},{"id":"T44273","span":{"begin":194,"end":198},"obj":"IN"},{"id":"T99668","span":{"begin":199,"end":200},"obj":"DT"},{"id":"T65524","span":{"begin":201,"end":211},"obj":"JJ"},{"id":"T66169","span":{"begin":212,"end":225},"obj":"JJ"},{"id":"T25963","span":{"begin":226,"end":240},"obj":"NN"},{"id":"T54040","span":{"begin":241,"end":242},"obj":"-LRB-"},{"id":"T15835","span":{"begin":242,"end":260},"obj":"NN"},{"id":"T75851","span":{"begin":261,"end":268},"obj":"NN"},{"id":"T55858","span":{"begin":268,"end":269},"obj":"-RRB-"},{"id":"T6426","span":{"begin":270,"end":274},"obj":"CC"},{"id":"T60445","span":{"begin":275,"end":289},"obj":"NN"},{"id":"T91733","span":{"begin":290,"end":291},"obj":"-LRB-"},{"id":"T10263","span":{"begin":291,"end":297},"obj":"CD"},{"id":"T89099","span":{"begin":297,"end":298},"obj":"-RRB-"},{"id":"T32422","span":{"begin":300,"end":305},"obj":"IN"},{"id":"T38661","span":{"begin":306,"end":315},"obj":"VBG"},{"id":"T47400","span":{"begin":316,"end":318},"obj":"TO"},{"id":"T27854","span":{"begin":319,"end":322},"obj":"DT"},{"id":"T88178","span":{"begin":323,"end":329},"obj":"JJ"},{"id":"T22917","span":{"begin":330,"end":334},"obj":"NN"},{"id":"T27562","span":{"begin":335,"end":337},"obj":"IN"},{"id":"T69861","span":{"begin":338,"end":347},"obj":"NN"},{"id":"T26688","span":{"begin":348,"end":366},"obj":"NN"},{"id":"T91618","span":{"begin":367,"end":371},"obj":"CC"},{"id":"T63033","span":{"begin":372,"end":378},"obj":"NN"},{"id":"T82872","span":{"begin":379,"end":393},"obj":"NN"},{"id":"T48110","span":{"begin":393,"end":394},"obj":"-COMMA-"},{"id":"T64285","span":{"begin":395,"end":398},"obj":"DT"},{"id":"T67888","span":{"begin":399,"end":401},"obj":"IN"},{"id":"T16788","span":{"begin":402,"end":405},"obj":"DT"},{"id":"T67776","span":{"begin":406,"end":414},"obj":"NNS"},{"id":"T6163","span":{"begin":415,"end":423},"obj":"VBN"},{"id":"T27596","span":{"begin":424,"end":426},"obj":"IN"},{"id":"T10929","span":{"begin":427,"end":430},"obj":"DT"},{"id":"T87507","span":{"begin":431,"end":439},"obj":"JJ"},{"id":"T10805","span":{"begin":439,"end":440},"obj":"-COMMA-"},{"id":"T49266","span":{"begin":441,"end":451},"obj":"NN"},{"id":"T95692","span":{"begin":451,"end":452},"obj":"-COMMA-"},{"id":"T51590","span":{"begin":453,"end":456},"obj":"CC"},{"id":"T63732","span":{"begin":457,"end":469},"obj":"JJ"},{"id":"T58895","span":{"begin":470,"end":478},"obj":"NNS"}],"relations":[{"id":"R50369","pred":"arg1Of","subj":"T21718","obj":"T18993"},{"id":"R14407","pred":"arg1Of","subj":"T21718","obj":"T64168"},{"id":"R76274","pred":"arg2Of","subj":"T66430","obj":"T64168"},{"id":"R38202","pred":"arg3Of","subj":"T95152","obj":"T64168"},{"id":"R86526","pred":"arg1Of","subj":"T21718","obj":"T31198"},{"id":"R31769","pred":"arg2Of","subj":"T65830","obj":"T31198"},{"id":"R46612","pred":"arg1Of","subj":"T65830","obj":"T55004"},{"id":"R25333","pred":"arg1Of","subj":"T65830","obj":"T56952"},{"id":"R9661","pred":"arg2Of","subj":"T98815","obj":"T56952"},{"id":"R66734","pred":"arg1Of","subj":"T98815","obj":"T69048"},{"id":"R31347","pred":"arg1Of","subj":"T98815","obj":"T75376"},{"id":"R59919","pred":"arg2Of","subj":"T24326","obj":"T75376"},{"id":"R40351","pred":"arg1Of","subj":"T24326","obj":"T59786"},{"id":"R92905","pred":"arg1Of","subj":"T31198","obj":"T13700"},{"id":"R16771","pred":"arg2Of","subj":"T13833","obj":"T13700"},{"id":"R26629","pred":"arg1Of","subj":"T13833","obj":"T79561"},{"id":"R4076","pred":"arg1Of","subj":"T13833","obj":"T83448"},{"id":"R17219","pred":"arg1Of","subj":"T21718","obj":"T77014"},{"id":"R22057","pred":"arg2Of","subj":"T31095","obj":"T77014"},{"id":"R79029","pred":"arg1Of","subj":"T31095","obj":"T40148"},{"id":"R1770","pred":"arg1Of","subj":"T77014","obj":"T13833"},{"id":"R37459","pred":"arg2Of","subj":"T80531","obj":"T13833"},{"id":"R47262","pred":"arg1Of","subj":"T21718","obj":"T80531"},{"id":"R34129","pred":"arg2Of","subj":"T11859","obj":"T80531"},{"id":"R19341","pred":"arg1Of","subj":"T3471","obj":"T26060"},{"id":"R92577","pred":"arg1Of","subj":"T3471","obj":"T11859"},{"id":"R40508","pred":"arg2Of","subj":"T65980","obj":"T11859"},{"id":"R18986","pred":"arg1Of","subj":"T65980","obj":"T6067"},{"id":"R39324","pred":"arg1Of","subj":"T13833","obj":"T58632"},{"id":"R49635","pred":"arg1Of","subj":"T13833","obj":"T52543"},{"id":"R4003","pred":"arg2Of","subj":"T6426","obj":"T52543"},{"id":"R22662","pred":"arg1Of","subj":"T84435","obj":"T44273"},{"id":"R78212","pred":"arg2Of","subj":"T25963","obj":"T44273"},{"id":"R70976","pred":"arg1Of","subj":"T25963","obj":"T99668"},{"id":"R50003","pred":"arg1Of","subj":"T25963","obj":"T65524"},{"id":"R2970","pred":"arg1Of","subj":"T25963","obj":"T66169"},{"id":"R89182","pred":"arg1Of","subj":"T25963","obj":"T54040"},{"id":"R82941","pred":"arg2Of","subj":"T75851","obj":"T54040"},{"id":"R99800","pred":"arg3Of","subj":"T55858","obj":"T54040"},{"id":"R95496","pred":"arg1Of","subj":"T75851","obj":"T15835"},{"id":"R36752","pred":"arg1Of","subj":"T84435","obj":"T6426"},{"id":"R79540","pred":"arg2Of","subj":"T60445","obj":"T6426"},{"id":"R41260","pred":"arg1Of","subj":"T60445","obj":"T91733"},{"id":"R75502","pred":"arg2Of","subj":"T10263","obj":"T91733"},{"id":"R50386","pred":"arg3Of","subj":"T89099","obj":"T91733"},{"id":"R26413","pred":"arg1Of","subj":"T6163","obj":"T32422"},{"id":"R62745","pred":"arg2Of","subj":"T38661","obj":"T32422"},{"id":"R35046","pred":"arg1Of","subj":"T64285","obj":"T38661"},{"id":"R97543","pred":"arg1Of","subj":"T38661","obj":"T47400"},{"id":"R45642","pred":"arg2Of","subj":"T22917","obj":"T47400"},{"id":"R79576","pred":"arg1Of","subj":"T22917","obj":"T27854"},{"id":"R56085","pred":"arg1Of","subj":"T22917","obj":"T88178"},{"id":"R64025","pred":"arg1Of","subj":"T22917","obj":"T27562"},{"id":"R36622","pred":"arg2Of","subj":"T91618","obj":"T27562"},{"id":"R47040","pred":"arg1Of","subj":"T26688","obj":"T69861"},{"id":"R96957","pred":"arg1Of","subj":"T26688","obj":"T91618"},{"id":"R59825","pred":"arg2Of","subj":"T82872","obj":"T91618"},{"id":"R2563","pred":"arg1Of","subj":"T82872","obj":"T63033"},{"id":"R17542","pred":"arg1Of","subj":"T6163","obj":"T48110"},{"id":"R33163","pred":"arg1Of","subj":"T64285","obj":"T67888"},{"id":"R47106","pred":"arg2Of","subj":"T67776","obj":"T67888"},{"id":"R68832","pred":"arg1Of","subj":"T67776","obj":"T16788"},{"id":"R41521","pred":"arg1Of","subj":"T64285","obj":"T6163"},{"id":"R92060","pred":"arg1Of","subj":"T6163","obj":"T27596"},{"id":"R79224","pred":"arg2Of","subj":"T58895","obj":"T27596"},{"id":"R14909","pred":"arg1Of","subj":"T58895","obj":"T10929"},{"id":"R43963","pred":"arg1Of","subj":"T58895","obj":"T87507"},{"id":"R46705","pred":"arg1Of","subj":"T87507","obj":"T10805"},{"id":"R31644","pred":"arg2Of","subj":"T49266","obj":"T10805"},{"id":"R53992","pred":"arg1Of","subj":"T58895","obj":"T49266"},{"id":"R52803","pred":"arg1Of","subj":"T51590","obj":"T95692"},{"id":"R16749","pred":"arg1Of","subj":"T10805","obj":"T51590"},{"id":"R63324","pred":"arg2Of","subj":"T63732","obj":"T51590"},{"id":"R41915","pred":"arg1Of","subj":"T58895","obj":"T63732"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T141","span":{"begin":104,"end":114},"obj":"Body_part"},{"id":"T142","span":{"begin":275,"end":289},"obj":"Body_part"},{"id":"T143","span":{"begin":379,"end":393},"obj":"Body_part"}],"attributes":[{"id":"A141","pred":"fma_id","subj":"T141","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A142","pred":"fma_id","subj":"T142","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A143","pred":"fma_id","subj":"T143","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T133","span":{"begin":42,"end":50},"obj":"Disease"}],"attributes":[{"id":"A133","pred":"mondo_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}

{"project":"LitCovid-sentences","denotations":[{"id":"T150","span":{"begin":0,"end":299},"obj":"Sentence"},{"id":"T151","span":{"begin":300,"end":479},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes."}